NVL-655 is a new experimental ALK inhibitor that is designed to treat ALK cancers, especially those that have become resistant to ALK inhibitors like lorlatinib, alectinib, and brigatinib. The study of this new drug is underway!

Clinical trial sites in the U.S. include Orange, California; Denver, Colorado; Boston, Massachusetts; Detroit, Michigan; New York, New York; Nashville, Tennessee; and Seattle, Washington. The expansion to Europe includes sites in Toulouse Cedex, France; Villejuif, France; and Barcelona, Spain.

To find out more visit: A Study of NVL-655 in Patients with Advanced NSCLC (ALKOVE-1)

ALK Positive, along with the University of Washington, is seeking more information about the experiences of those diagnosed with ALK-positive lung cancer. They have created a survey with many points of interest, including the experiences of those who have participated in clinical trials. The survey is confidential and approved by a research governing body.

To complete the survey, please click here: ALK-positive Lung Cancer Registry and Survey

ALK LUNG CANCER CLINICAL TRIAL HELP AND SEARCHING

ALK Positive Support Group Clinical Trials Spreadsheet*

This Clinical Trials Spreadsheet above, compiled by Ellee Urban, only lists active trials.

It only lists trails for which ALK+ patients are eligible
It lists 48 trials that are for non-lung, and 93 trials for lung cancer.
It lists 22 trials not yet recruiting.
It breaks down trial availability by Americas/ Europe/ Australia/ China/ other.
It breaks down trial availability by line of treatment
It breaks down trial availability by stage of cancer.
It breaks down trial availability by trial phase.

OTHER RESOURCES:

LUNGevity Online Clinical Trial Finder

CenterWatch Clinical Trials Search

MassiveBio Clinical Trials Search

General Info about ALK NSCLC Clinical Trials

As of January 2023, there are at least 50 clinical trials that are recruiting specifically for people with ALK-positive lung cancer. Many of these trials have multiple sites worldwide. Since ALK-positive lung cancer is a rare disease, it is difficult for any one oncologist to be aware of all the trials available. You can advocate for yourself and find a clinical trial that may be a good fit for you at any juncture in treatment.

*The ALK Positive Clinical Trials Spreadsheet was developed by the ALK Positive Medical Committee. The database is updated monthly. Disclaimer: these trials have been consolidated by volunteers and should not be considered exhaustive. Listing of these trials is not an endorsement, and ALK Positive does not recommend one trial over another. Please talk with your doctor about these or any trials you are interested in.

Author: Ellee Urban

The New ALK Inhibitor: NVL-655 Trial Expands to Europe!